ArticleSensors (Basel, Switzerland)2026
An Agentic Multimodal Sensing Architecture for CT-Guided Wearable and Respiratory Monitoring in Oncology Care.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Oncology care increasingly depends on heterogeneous sensing streams generated by computed tomography (CT), radiotherapy planning systems, wearable devices, home respiratory sensors, patient-reported outcomes, and clinical records. These data streams are often processed separately, limiting their value for longitudinal, context-aware review. This study proposes OncoSense-Agent, a reliability-aware agentic multimodal sensing architecture for CT-guided respiratory monitoring in oncology care. The architecture links CT-derived anatomical evidence with wearable physiology, respiratory symptoms, functional assessment, treatment context, and explainable human-in-the-loop review-priority generation. To move beyond a purely conceptual design, we implemented a lung-focused proof-of-concept with six bounded software agents: Imaging Reliability, Wearable Monitoring, Respiratory Review, Treatment Context, Multimodal Fusion, and Explainability. The prototype used real nnU-Net v2 3D lung segmentation metrics from 139 patients with complete bilateral lung CT data as the imaging anchor, while wearable, respiratory, symptom, and treatment-context channels were introduced as deterministic overlays for controlled validation. OncoSense-Agent changed review-priority assignment relative to CT-only assessment in 78/139 cases (56.1%), assigned 111/139 cases (79.9%) to high-priority or high-uncertainty tiers, and showed increasing Safety Gate activation as CT quality declined. Three illustrative cases demonstrate hidden respiratory deterioration, wearable data-quality uncertainty, and treatment-context risk not captured by CT-only assessment. The prototype does not establish clinical diagnostic accuracy, but demonstrates operational, auditable, reliability-aware multimodal review-priority generation for clinician-supervised oncology monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.